Christoph Licht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9177024/publications.pdf

Version: 2024-02-01

155 papers	7,832 citations	66343 42 h-index	53230 85 g-index
158 all docs	158 docs citations	158 times ranked	7364 citing authors

#	Article	IF	Citations
1	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	1.7	445
2	Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genetics in Medicine, 2018, 20, 435-443.	2.4	404
3	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	5.2	342
4	Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood, 2008, 111, 1512-1514.	1.4	332
5	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology, 2009, 24, 687-696.	1.7	315
6	Deletion of Complement Factor Hâ€“Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome. PLoS Genetics, 2007, 3, e41.	3.5	285
7	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International, 2012, 81, 494-501.	5.2	275
8	Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood, 2013, 122, 2003-2007.	1.4	237
9	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231
10	Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantationâ€“Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2014, 20, 518-525.	2.0	218
11	Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International, 2016, 89, 701-711.	5.2	210
12	Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nature Genetics, 2013, 45, 1375-1379.	21.4	158
13	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	13.7	132
14	NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Frontiers in Immunology, 2016, 7, 137.	4.8	123
15	aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology, 2011, 26, 41-57.	1.7	122
16	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrology, 2013, 28, 5-11.	1.7	118
17	Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Seminars in Thrombosis and Hemostasis, 2014, 40, 444-464.	2.7	117
18	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andÂoutcome. Kidney International, 2018, 94, 408-418.	5.2	117

#	Article	IF	Citations
19	Factor H and Atypical Hemolytic Uremic Syndrome: Mutations in the C-Terminus Cause Structural Changes and Defective Recognition Functions. Journal of the American Society of Nephrology: JASN, 2006, 17, 170-177.	6.1	115
20	Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. American Journal of Kidney Diseases, 2005, 45, 415-421.	1.9	113
21	Eculizumab and Refractory Membranoproliferative Glomerulonephritis. New England Journal of Medicine, 2012, 366, 1165-1166.	27.0	113
22	Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney International, 2012, 81, 779-783.	5.2	113
23	FAT1 mutations cause a glomerulotubular nephropathy. Nature Communications, 2016, 7, 10822.	12.8	99
24	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	1.7	95
25	C3 deposition glomerulopathy due to a functional Factor H defect. Kidney International, 2009, 75, 1230-1234.	5.2	79
26	Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrology, 2019, 20, 125.	1.8	77
27	DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatric Nephrology, 2010, 25, 2009-2019.	1.7	72
28	Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood, 2009, 114, 4538-4545.	1.4	70
29	C3 Glomerulopathy. Pediatric Nephrology, 2017, 32, 43-57.	1.7	67
30	Antibody Mediated Rejection Associated With Complement Factor Hâ€“Related Protein 3/1 Deficiency Successfully Treated With Eculizumab. American Journal of Transplantation, 2012, 12, 2546-2553.	4.7	61
31	Eculizumab in Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2013, 369, 1377-1380.	27.0	61
32	Effects of Hemodiafiltration versus Conventional Hemodialysis in Children with ESKD: The HDF, Heart and Height Study. Journal of the American Society of Nephrology: JASN, 2019, 30, 678-691.	6.1	60
33	Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy. Journal of Immunology, 2013, 191, 2184-2193.	0.8	59
34	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2019, 4, 434-446.	0.8	59
35	Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thrombosis and Haemostasis, 2009, 101, 271-278.	3.4	58
36	Von Willebrand factor regulates complement on endothelial cells. Kidney International, 2016, 90, 123-134.	5.2	53

#	Article	IF	Citations
37	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
38	The global aHUS registry: methodology and initial patient characteristics. BMC Nephrology, 2015, 16, 207.	1.8	52
39	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
40	Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney International, 2004, 66, 955-958.	5.2	48
41	Pandemic H1N1 influenza A infection and (atypical) HUSâ€"more than just another trigger?. Pediatric Nephrology, 2011, 26, 3-5.	1.7	46
42	Rare diseases and effective treatments: are we delivering?. Lancet, The, 2015, 385, 750-752.	13.7	46
43	Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Molecular Immunology, 2009, 46, 2801-2807.	2.2	44
44	Endothelin-1 Induces NF-ÎºB via Two Independent Pathways in Human Renal Tubular Epithelial Cells. American Journal of Nephrology, 2007, 27, 294-300.	3.1	41
45	Prolonged survival in alveolar capillary dysplasia syndrome. European Journal of Pediatrics, 2004, 163, 181-182.	2.7	40
46	Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrology Dialysis Transplantation, 2008, 24, 731-734.	0.7	40
47	The Impact of Hypoparathyroidism Treatment on the Kidney in Children: Long-Term Retrospective Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4106-4113.	3.6	40
48	Eculizumab hepatotoxicity in pediatric aHUS. Pediatric Nephrology, 2015, 30, 775-781.	1.7	39
49	MPGN II â€“ genetically determined by defective complement regulation?. Pediatric Nephrology, 2007, 22, 2-9.	1.7	37
50	An autocrine role for endothelin-1 in the regulation of proximal tubule NHE3. Kidney International, 2004, 65, 1320-1326.	5.2	36
51	Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatric Nephrology, 2014, 29, 779-792.	1.7	36
52	Successful treatment of DEAP-HUS with eculizumab. Pediatric Nephrology, 2014, 29, 841-851.	1.7	36
53	The Role of Defective Complement Control in Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 146-154.	2.7	35
54	C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatric Nephrology, 2016, 31, 2079-2086.	1.7	35

#	Article	IF	Citations
55	Inherited Kidney Complement Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 942-956.	4.5	34
56	Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatric Nephrology, 2013, 28, 2289-2298.	1.7	33
57	Relative antibacterial functions of complement and NETs: NETs trap and complement effectively kills bacteria. Molecular Immunology, 2018, 97, 71-81.	2.2	33
58	The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik, 2018, 30, 400-409.	0.2	33
59	Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings. Pediatric Nephrology, 2018, 33, 1773-1780.	1.7	32
60	Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney International Reports, 2017, 2, 66-75.	0.8	29
61	Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results. Blood, 2012, 120, 985-985.	1.4	28
62	Severe atypical HUS caused by CFH S1191Lâ€"case presentation and review of treatment options. Pediatric Nephrology, 2010, 25, 97-104.	1.7	27
63	An update on the pathomechanisms and future therapies of Alport syndrome. Pediatric Nephrology, 2013, 28, 1025-1036.	1.7	27
64	Detection of Polyomavirus BK and JC in Children With Kidney Diseases and Renal Transplant Recipients. Pediatric Infectious Disease Journal, 2005, 24, 778-781.	2.0	26
65	Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thrombosis and Haemostasis, 2009, 101, 271-8.	3.4	26
66	Community-acquired pneumonia due to Bordetella holmesii in a patient with frequently relapsing nephrotic syndrome. Journal of Infection, 2007, 54, e203-e205.	3.3	23
67	Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Molecular Immunology, 2013, 54, 84-88.	2.2	23
68	An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet Journal of Rare Diseases, 2016, 11, 154.	2.7	22
69	Effect of haemodiafiltration vs conventional haemodialysis on growth and cardiovascular outcomes in children â€“ the HDF, heart and height (3H) study. BMC Nephrology, 2018, 19, 199.	1.8	22
70	The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2013, 28, 939-949.	1.7	21
71	Comparison of two apheresis systems for autologous stem cell collections in pediatric oncology patients. Transfusion, 2017, 57, 122-130.	1.6	21
72	Osteopontin Mediates Citrobacter rodentium-Induced Colonic Epithelial Cell Hyperplasia and Attaching-Effacing Lesions. American Journal of Pathology, 2010, 177, 1320-1332.	3.8	20

#	Article	IF	Citations
73	Hemolytic uremic syndrome caused by Bordetella pertussis infection. Pediatric Nephrology, 2010, 25, 1361-1364.	1.7	19
74	Pathogenesis and treatment of ANCA-associated vasculitisâ€"a role for complement. Pediatric Nephrology, 2018, 33, 1-11.	1.7	19
75	Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H. Frontiers in Immunology, 2020, 11, 1833.	4.8	19
76	Behavioural abnormalities in children with nephrotic syndrome--an underappreciated complication of a standard treatment?. Nephrology Dialysis Transplantation, 2010, 25, 2397-2399.	0.7	18
77	CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatric Nephrology, 2016, 31, 157-161.	1.7	18
78	Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110087.	1.1	18
79	Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. CKJ: Clinical Kidney Journal, 2019, 12, 196-205.	2.9	16
80	An upfront immunomodulatory therapy protocol for pediatric opsoclonusâ€•myoclonus syndrome. Pediatric Blood and Cancer, 2019, 66, e27776.	1.5	16
81	Genetics of Proteinuria: An Overview of Gene Mutations Associated with Nonsyndromic Proteinuric Glomerulopathies. Advances in Chronic Kidney Disease, 2011, 18, 273-289.	1.4	15
82	Nocturnal enuresis in adolescents with anorexia nervosa: Prevalence, potential causes, and pathophysiology. International Journal of Eating Disorders, 2011, 44, 349-355.	4.0	15
83	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
84	Remission of resistant MPGN type I with mycophenolate mofetil and steroids. Pediatric Nephrology, 2009, 24, 597-600.	1.7	14
85	Impact of fill volume on ultrafiltration with icodextrin in children on chronic peritoneal dialysis. Pediatric Nephrology, 2016, 31, 1673-1679.	1.7	14
86	Renal replacement therapy in the management of intoxications in children: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) workgroup. Pediatric Nephrology, 2019, 34, 2427-2448.	1.7	14
87	Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney International Reports, 2020, 5, 2313-2324.	0.8	14
88	The alternative pathway of complement and the thrombotic microangiopathies. Transfusion and Apheresis Science, 2016, 54, 220-231.	1.0	13
89	Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight, 2022, 7, .	5.0	13
90	Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with highâ€•risk leukemia. Transfusion, 2017, 57, 1536-1542.	1.6	12

#	Article	IF	Citations
91	Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency. CKJ: Clinical Kidney Journal, 2018, 11, 310-314.	2.9	12
92	Vascular endothelial cells evade complementâ€mediated membrane injury via Weibelâ€Palade body mobilization. Journal of Thrombosis and Haemostasis, 2020, 18, 1484-1494.	3.8	12
93	Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. Kidney International Reports, 2020, 5, 1161-1171.	0.8	12
94	Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study. Kidney International Reports, 2021, 6, 2358-2370.	0.8	11
95	Association of outcomes in acute flaccid myelitis with identification of enterovirus at presentation: a Canadian, nationwide, longitudinal study. The Lancet Child and Adolescent Health, 2020, 4, 828-836.	5.6	9
96	Hemodiafiltration maintains a sustained improvement in blood pressure compared to conventional hemodialysis in childrenâ€"the HDF, heart and height (3H) study. Pediatric Nephrology, 2021, 36, 2393-2403.	1.7	9
97	Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy. Pediatric Nephrology, 2011, 26, 979-985.	1.7	8
98	The role of von Willebrand factor in thrombotic microangiopathy. Pediatric Nephrology, 2018, 33, 1297-1307.	1.7	8
99	Hemodialysis Catheters in Infants: AÂRetrospective Single-Center Cohort Study. Journal of Vascular and Interventional Radiology, 2020, 31, 778-786.	0.5	8
100	Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatric Nephrology, 2022, 37, 1479-1493.	1.7	8
101	Treatment of paediatric vancomycin intoxication: a case report and review of the literature. CKJ: Clinical Kidney Journal, 2010, 3, 260-264.	2.9	7
102	Trends in pediatric primary membranoproliferative glomerulonephritis costs and complications. Pediatric Nephrology, 2012, 27, 2243-2250.	1.7	6
103	Short, frequent, 5-days-per-week, in-center hemodialysis versus 3-days-per week treatment: a randomized crossover pilot trial through the Midwest Pediatric Nephrology Consortium. Pediatric Nephrology, 2017, 32, 1423-1432.	1.7	6
104	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. Journal of Allergy and Clinical Immunology, 2021, 147, 749-753.e2.	2.9	6
105	The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms, 2021, 9, 2157.	3.6	6
106	Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR. Journal of Clinical Medicine, 2018, 7, 324.	2.4	5
107	Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435811989722.	1.1	5
108	Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells. Toxins, 2020, 12, 483.	3.4	4

#	Article	IF	Citations
109	Reversal of Stroke-Like Episodes With L-Arginine and Meticulous Perioperative Management of Renal Transplantation in a Patient With Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome. Case Report. Neurohospitalist, The, 2022, 12, 67-73.	0.8	4
110	Bloodâ€“brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study. Blood Advances, 2021, 5, 4211-4218.	5.2	4
111	Shiga Toxin 2a Induces NETosis via NOX-Dependent Pathway. Biomedicines, 2021, 9, 1807.	3.2	4
112	Long-term Eculizumab Therapy in a Child With Refractory Immune Complexâ€“Mediated Membranoproliferative Glomerulonephritis. Kidney International Reports, 2018, 3, 482-485.	0.8	3
113	The Role of Complement in the Pathogenesis of HUS and the TMA Spectrum Disorders. Current Pediatrics Reports, 2019, 7, 1-11.	4.0	3
114	Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy. Kidney International Reports, 2021, 6, 1669-1676.	0.8	3
115	Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,. Blood, 2011, 118, 3303-3303.	1.4	3
116	Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2011, 118, 4772-4772.	1.4	3
117	Posttransplant lymphoproliferative disease in a child: clinical and molecular characterization. Pediatric Nephrology, 2002, 17, 79-84.	1.7	2
118	Treatment of DEAP-HUSâ€”seeking the best strategy. Pediatric Nephrology, 2014, 29, 941-942.	1.7	2
119	Membranoproliferative and C3-Mediated GN in Children. , 2016, , 1035-1053.		2
120	Canadian Association of Paediatric Nephrologists COVID-19 Rapid Response: Guidelines for Management of Acute Kidney Injury in Children. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812199013.	1.1	2
121	Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin. International Journal of Molecular Sciences, 2021, 22, 5615.	4.1	2
122	Membranoproliferative Glomerulonephritis. , 2009, , 783-797.		2
123	Complement Factor H in Human Platelets: Implications for Atypical HUS.. Blood, 2008, 112, 1833-1833.	1.4	2
124	Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update. Blood, 2014, 124, 4986-4986.	1.4	2
125	Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 2252-2252.	1.4	2
126	Hemolytic Uremic Syndrome. , 2011, , 277-297.		1

#	Article	IF	Citations
127	An atypical case of acute kidney injury: Questions. Pediatric Nephrology, 2016, 31, 917-917.	1.7	1
128	An atypical case of acute kidney injury: Answers. Pediatric Nephrology, 2016, 31, 919-921.	1.7	1
129	Plastic bronchitis: a rare complication of long-term haemodialysis catheter placement in a child. Pediatric Nephrology, 2017, 32, 1635-1638.	1.7	1
130	Neonatal stroke and haematuria: Questions. Pediatric Nephrology, 2018, 33, 805-806.	1.7	1
131	FP250FACIT-FATIGUE SCORES IN ADULT PATIENTS AT ENROLLMENT INTO THE GLOBAL AHUS REGISTRY. Nephrology Dialysis Transplantation, 2018, 33, i114-i114.	0.7	1
132	Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children. , 2021, , 1-31.		1
133	Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration. Kidney International Reports, 2021, 6, 1003-1014.	0.8	1
134	GlomerulÃre Erkrankungen. , 2017, , 69-123.		1
135	Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.. Blood, 2012, 120, 2085-2085.	1.4	1
136	Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab. Blood, 2013, 122, 2186-2186.	1.4	1
137	Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2013, 122, 2191-2191.	1.4	1
138	The Role of Complement in Disease. , 2016, , 583-596.		1
139	FC 115: Long-Term Outcomes in Eculizumab-Treated Kidney Transplant Patients Enrolled in the Global Atypical Haemolytic Uraemic Syndrome Registry. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
140	Membranoproliferative Glomerulonephritis. , 2008, , 269-289.		0
141	SP149ECULIZUMAB TREATMENT OF SHIGA TOXIN ESCHERICHIA COLI HEMOLYTIC UREMIC SYNDROME. Nephrology Dialysis Transplantation, 2017, 32, iii154-iii154.	0.7	0
142	Is there a case for eculizumab for pediatric renal transplantation?. Pediatric Transplantation, 2018, 22, e13128.	1.0	0
143	Neonatal stroke and haematuria: Answers. Pediatric Nephrology, 2018, 33, 807-811.	1.7	0
144	SP022IMPAIRED ENDOTHELIAL CELL MIGRATION: NEW INSIGHTS INTO THE MECHANISMS OF COMPLEMENT-MEDIATED ENDOTHELIAL CELL INJURY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0

#	Article	IF	Citations
145	Helping nephrologists find answers: hyperinsulinism and tubular dysfunction: Questions. Pediatric Nephrology, 2020, 35, 253-255.	1.7	0
146	Helping nephrologists find answers: hyperinsulinism and tubular dysfunction: Answers. Pediatric Nephrology, 2020, 35, 257-260.	1.7	0
147	MO107CLINICAL CHARACTERISTICS OF A PATIENT POPULATION WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME AND MALIGNANT HYPERTENSION: THE GLOBAL AHUS REGISTRY ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
148	Implementing a fluid volume management program to decrease intra-dialytic hypotensive events in a paediatric in-centre haemodialysis unit: a quality improvement project. Pediatric Nephrology, 2021, , 1.	1.7	0
149	Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry. Blood, 2014, 124, 4204-4204.	1.4	0
150	Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience. Blood, 2014, 124, 4186-4186.	1.4	0
151	Membranoproliferative and C3-Mediated GN in Children. , 2015, , 1-22.		0
152	The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 4640-4640.	1.4	0
153	C3 Glomerulopathies. , 2016, , 633-649.		0
154	Peripheral Venous Access for Collection of Immune Effector Cells and Hematopoietic Stem Cells Is Feasible and Safe in Older Children and Young Adult Patients. Blood, 2020, 136, 19-20.	1.4	0
155	Response to the Letter to the Editor â€œ The apparent beneficial effect of L-arginine for stroke-like lesions can be accidental â€œ by Josef Finsterer and Sinda Zarrouk. Neurohospitalist, The, 0, , 194187442210902.	0.8	0